Navigation Links
Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
Date:10/27/2009

FRAZER, Pa., Oct. 27 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2009 net sales of $535.2 million, a 9 percent increase compared to net sales of $489.7 million for the third quarter 2008. Basic income per common share for the quarter was $1.38. Excluding amortization expense and certain other items, basic adjusted income per common share for the quarter was $1.70, an increase of 25 percent over the comparable figure of $1.36 for the same period in 2008. Adjusted net income for the third quarter of 2009 was $126.7 million, a 36 percent increase over the comparable $92.9 million for the third quarter of 2008. This exceeded the company's adjusted net income guidance range of $108 to $116 million.

Central nervous system (CNS) franchise net sales were $291.9 million during the quarter, a 7 percent increase compared to the same period last year. Pain franchise reported net sales of $116.3 million, a 1 percent decrease versus third quarter 2008. Oncology franchise net sales were $83.1 million, a 58 percent increase over the same period last year due to strong sales of TREANDA® (bendamustine hydrochloride) of $54.5 million.

During the quarter Cephalon recorded net cash provided by operating activities of $203.6 million bringing the year-to-date cash flow from operations to $517.1 million.

"The exceptional launch of NUVIGIL was the highlight of the quarter," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "In addition, we have assembled the deepest and most diverse pipeline in our history with a variety of small molecules and biologics being studied for pain, oncology, and inflammatory diseases. We look forward to developing this diverse pipeline with the goal of creating important new medicines for patients."

The company is updating its guidance for 2009.
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)...  AbbVie (NYSE: ABBV ) has announced that ... its New Drug Application (NDA) and granted priority review ... of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The ... genotype 4 (GT4) hepatitis C virus (HCV) infection. ... being evaluated by the FDA for patients in ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
(Date:4/23/2015)... FRANCISCO , April 23, 2015 Nektar Therapeutics ... the first quarter ended March 31, 2015 on Thursday, April ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company ... from its consumer trial with Allumera™, a breakthrough cosmetic ... The RevitAll study was performed with a standard ... Allumera™ improves skin appearance, when compared to exposure by ...
... Inc. (Hologic or the Company) (Nasdaq: ... of premium diagnostics products, medical imaging systems and ... of women, announced today the U.S. Food and ... Makena™ (hydroxyprogesterone caproate injection), formerly known as Gestiva™. ...
Cached Medicine Technology:Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 2Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 3Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 4FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical 2
(Date:4/26/2015)... With the FCPX LUT B&W pack from Pixel ... quickly and easily add desaturated color grades to footage. A ... for modifying an image. The LUT changes every pixel's color ... comes with 60 black and white CUBE LUT files. , ... white films. With the FCPX LUT B&W Loader from ...
(Date:4/26/2015)... 2015 In an article published last ... the head-neck biomechanics occurring during the use of handheld electronic ... to determine that use of a tablet increases mechanical demand ... times - more than when the neck is in a ... study, but pointing out the potential hazards of overuse of ...
(Date:4/25/2015)... (PRWEB) April 26, 2015 Diversified ... based integrative healthcare event. The Integrative Healthcare Symposium ... October 23-24, 2015 at the Sheraton Parkway Toronto ... Canada is one of the most anticipated events ... relevant, evidenced-based CME program. The event aims to ...
(Date:4/25/2015)... York (PRWEB) April 25, 2015 ... for vaginal mesh lawsuits filed against C.R. Bard, ... District Court, Southern District of West Virginia. According ... Scheduling Conference was convened that day, after certain ... Long Form Complaint. The Order directed that any ...
(Date:4/25/2015)... 2015 Gardant Management Solutions will ... and operations, and sales and marketing at the ... to be held from April 29 through May ... the largest eldercare association in Illinois. The statewide ... older adults, including senior housing, assisted living and ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios, a FCPX Effects Developer, Announced the Release of FCPX LUT B&W 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Integrative Healthcare Event launching in Canada 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Gardant Management Solutions Staff Shares Operational Expertise 2
... THURSDAY, June 9 (HealthDay News) -- With record-breaking heat searing ... and with little relief in sight -- health experts are ... oppressive temperatures and humidity. "The elderly, young children and ... taking certain medications, especially antidepressants, are most at risk ...
... new study published today in the inaugural issue of the ... by tracking pharmacy purchases of anti-Parkinson drugs they could estimate ... population. The study identified a sharp rise in PD prevalence ... which warrants further investigation. Surprisingly, much of the world ...
... Steven Reinberg HealthDay Reporter , THURSDAY, June 9 ... treated in hospital emergency rooms for injuries sustained in bathrooms ... in the June 10 issue of the U.S. Centers ... Report , indicate that most of these injuries -- 80 ...
... In a study published today in the Clinical ... Kennedy Krieger Institute found differences in the brain development ... Results showed the region of the brain important for ... than in typically developing children. Novel for its use ...
... Reporter , WEDNESDAY, June 8 (HealthDay News) -- Women offered ... time they,re having a uterine aspiration due to miscarriage or ... women offered one later on, new research suggests. The ... inserted immediately after a uterine aspiration is higher than it ...
... gene linked to emphysema also can be a factor for ... Center research indicates. Smoking was the only known risk factor ... mice bred to have the human gene pleiomorphic adenoma gene-like ... lung cancer at rates as high as one in every ...
Cached Medicine News:Health News:Record Temperatures Posing Health Risks in U.S. 2Health News:Record Temperatures Posing Health Risks in U.S. 3Health News:New method for measuring Parkinson's disease prevalence reveals sharp increase in Israel 2Health News:Bathroom Injuries a Little-Known Problem 2Health News:Brain imaging study of preschoolers with ADHD detects brain differences linked to symptoms 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 3Health News:UT Southwestern research uncovers genetic link between emphysema, lung cancer 2
... includes everything from the care package ... Spare Fluorescent Bulb, additional Vibratome Feather ... and a Specimen Tray. ... 1/2" speciment mounts, replacement rotating mounts, ...
... The Specimen Tray accessory fits inside the ... removable working area for tissue sectioning. Specimens ... specimen tray. This is a great option ... an expensive buffer, or wish to utilize the ...
... inside the existing black Vibratome bath. This ... buffer and ice kept in the original black ... has round mounting disks that can be easily ... bath surface are marked with degrees of rotation ...
... This unit provides a convenient reservoir of cooling ... operated for an extended period of time or in ... nearby to cool the hot side of the thermoelectric ... of water, which is adequate to run the 900R ...
Medicine Products: